Paper39208374
A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease.
Mahal BA and 8 others. JCO Precis Oncol, 2024. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease. Papers, record 39208374. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39208374
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Early Detection of Cancer | Major topic |
| Neoplasm Grading | Major topic |
| Prostatic Neoplasms | Major topic |
| Aged | |
| Humans | |
| Male | |
| Middle Aged | |
| DNA Methylation | |
| Overdiagnosis | |
| Prospective Studies |
Source PubMed
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT02889978 | The Circulating Cell-free Genome Atlas Study | Derived from the trial | Yes | ClinicalTrials.gov |
| NCT04241796 | Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test Into Clinical Practice | Derived from the trial | Yes | ClinicalTrials.gov |
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Erratum in | 39413340 | Erratum: A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease. | https://conductscience.org/library/papers/39413340 | PubMed |
| Comment in | 39298695 | Progress and Promise for Multicancer Early Detection Testing in Prostate Cancer. | https://conductscience.org/library/papers/39298695 | PubMed |
References20
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32554709 | ctDNA monitoring using patient-specific sequencing and integration of variant reads. | Sci Transl Med | 2020 | https://conductscience.org/library/papers/32554709 | PubMed |
| 2 | 35948080 | Circulating Tumor DNA Allele Fraction: A Candidate Biological Signal for Multicancer Early Detection Tests to Assess the Clinical Significance of Cancers. | Am J Pathol | 2022 | https://conductscience.org/library/papers/35948080 | PubMed |
| 3 | 24439788 | Overdiagnosis and overtreatment of prostate cancer. | Eur Urol | 2014 | https://conductscience.org/library/papers/24439788 | PubMed |
| 4 | 34432811 | Clinical correlates of circulating cell-free DNA tumor fraction. | PLoS One | 2021 | https://conductscience.org/library/papers/34432811 | PubMed |
| 5 | 37805216 | Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. | Lancet | 2023 | https://conductscience.org/library/papers/37805216 | PubMed |
| 6 | 38201510 | A Novel Tissue-Free Method to Estimate Tumor-Derived Cell-Free DNA Quantity Using Tumor Methylation Patterns. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/38201510 | PubMed |
| 7 | 14519749 | Comparing survival of a sample to that of a standard population. | J Natl Cancer Inst | 2003 | https://conductscience.org/library/papers/14519749 | PubMed |
| 8 | 31142840 | Genome-wide cell-free DNA fragmentation in patients with cancer. | Nature | 2019 | https://conductscience.org/library/papers/31142840 | PubMed |
| 9 | 33506766 | Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. | Ann Oncol | 2020 | https://conductscience.org/library/papers/33506766 | PubMed |
| 10 | 24553385 | Detection of circulating tumor DNA in early- and late-stage human malignancies. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24553385 | PubMed |
| 11 | 31528835 | Low Abundance of Circulating Tumor DNA in Localized Prostate Cancer. | JCO Precis Oncol | 2019 | https://conductscience.org/library/papers/31528835 | PubMed |
| 12 | 37255363 | Dying To Find Out: The Cost of Time at the Dawn of the Multicancer Early Detection Era. | Cancer Epidemiol Biomarkers Prev | 2023 | https://conductscience.org/library/papers/37255363 | PubMed |
| 13 | 37927174 | The enigma of race and prostate cancer. | Cancer | 2024 | https://conductscience.org/library/papers/37927174 | PubMed |
| 14 | 34426664 | Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK. | Br J Cancer | 2021 | https://conductscience.org/library/papers/34426664 | PubMed |
| 15 | 34176681 | Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. | Ann Oncol | 2021 | https://conductscience.org/library/papers/34176681 | PubMed |
| 16 | 33658587 | Cell-free DNA concentration and fragment size as a biomarker for prostate cancer. | Sci Rep | 2021 | https://conductscience.org/library/papers/33658587 | PubMed |
| 17 | 29348365 | Detection and localization of surgically resectable cancers with a multi-analyte blood test. | Science | 2018 | https://conductscience.org/library/papers/29348365 | PubMed |
| 18 | 38424555 | Association between patient ethnicity and prostate cancer diagnosis following a prostate-specific antigen test: a cohort study of 730,000 men in primary care in the UK. | BMC Med | 2024 | https://conductscience.org/library/papers/38424555 | PubMed |
| 19 | 38378299 | Ultrasensitive Detection of Circulating Tumour DNA enriches for Patients with a Greater Risk of Recurrence of Clinically Localised Prostate Cancer. | Eur Urol | 2024 | https://conductscience.org/library/papers/38378299 | PubMed |
| 20 | 36400018 | Evaluation of cell-free DNA approaches for multi-cancer early detection. | Cancer Cell | 2022 | https://conductscience.org/library/papers/36400018 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42388617 | Early detection of multiple cancers: the era of methylation-based liquid biopsy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42388617 | PubMed |
| 41818645 | Prognostic Significance of Blood-Based Multicancer Detection in Circulating Tumor DNA: Five-Year Outcomes Analysis. | JCO Precis Oncol | 2026 | https://conductscience.org/library/papers/41818645 | PubMed |
| 41480180 | Liquid biopsy in genitourinary cancers: Diagnostic and prognostic implications. | World J Clin Oncol | 2025 | https://conductscience.org/library/papers/41480180 | PubMed |
| 40979549 | Emerging tools for the early detection of prostate cancer. | BJUI Compass | 2025 | https://conductscience.org/library/papers/40979549 | PubMed |
| 40863429 | The Evolving Landscape of Novel and Old Biomarkers in Localized High-Risk Prostate Cancer: State of the Art, Clinical Utility, and Limitations Toward Precision Oncology. | J Pers Med | 2025 | https://conductscience.org/library/papers/40863429 | PubMed |
| 40749671 | Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications. | Cancer Cell | 2025 | https://conductscience.org/library/papers/40749671 | PubMed |
| 40323021 | Modeled Benefit of Individual Cancer Signal Origin Prediction for Multi-Cancer Early Detection. | Cancer Res Commun | 2025 | https://conductscience.org/library/papers/40323021 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39208374
GET https://conductscience.org/api/papers/v1/39208374/authors